| Literature DB >> 31168415 |
Marthe Halsan Liff1,2, Mari Hoff3,4, Thomas Fremo5, Ulrik Wisløff5, Ranjeny Thomas6, Vibeke Videm2,7.
Abstract
Objective: Patients with rheumatoid arthritis (RA) suffer from more cardiovascular disease (CVD), and develop cardiovascular risk factors at an earlier age than the general population. Cardiorespiratory fitness (CRF) is an important predictor of cardiovascular health. There are few data regarding CRF of RA patients, measured as peak oxygen uptake (VO2peak) by the gold standard method; cardiopulmonary exercise testing. We compared CRF in RA patients to those from a healthy population, and investigated if risk factors for CVD and RA-specific variables including subjective and objective disease activity measures were associated with CRF in RA patients.Entities:
Keywords: cardiovascular disease; epidemiology; patient perspective; rheumatoid arthritis
Year: 2019 PMID: 31168415 PMCID: PMC6525607 DOI: 10.1136/rmdopen-2019-000912
Source DB: PubMed Journal: RMD Open ISSN: 2056-5933
Figure 1Recruitment to the study. RA, rheumatoid arthritis; VES, ventricular extrasystoles.
Patient characteristics
| Patient characteristics | Total n=93 | Women n=68 | Men n=25 |
| Age median, (IQR) | 60 (52–66) | 60 (51–67) | 60 (52–66) |
| Height (m), mean (SD) | 1.69 (0.90) | 1.66 (0.63) | 1.80 (0.71) |
| Weight (kg), mean (SD) | 76.4 (12.3) | 72.7 (10.9) | 86.8 (9.7) |
| Body mass index (kg/m2), mean (SD) | 26.7 (3.9) | 26.6 (4.1) | 26.9 (3.4) |
| Comorbidity, n (%) | 38 (41) | 30 (44) | 8 (32) |
| Cardiovascular (HT, angina, MI) | 21 (23) | 17 (25) | 4 (16) |
| Respiratory (COPD and/or CRPD) | 18 (19) | 15 (22) | 3 (12) |
| Diabetes | 4 (4) | 3 (4) | 1 (4) |
| Cancer (previous or present) | 5 (5) | 3 (4) | 2 (8) |
| Smoking, n (%)* | |||
| Never smoked | 35 (38) | 27 (40) | 8 (32) |
| Previous smoker | 51 (55) | 37 (54) | 14 (56) |
| Present smoker | 7 (8) | 4 (6) | 3 (12) |
| Resting heart rate (beats per min), mean (SD) | 66 (10) | 67 (9) | 65 (11) |
| Physical activity categories, n (%) | |||
| Does not fulfil ACSM/AHA recommendations | 64 (69) | 44 (66) | 19 (76) |
| Fulfils ACSM/AHA recommendations | 29 (31) | 23 (34) | 6 (24) |
| Seropositivity (ACPA and/or RF), n (%) | 75 (81) | 54 (79) | 21 (84) |
| Disease duration (years), median (IQR) | 10 (5–19) | 10 (5–20) | 11 (6–16) |
| Patient global assessment (0–100 mm), median (IQR) | 24 (10–36) | 27 (16–42) | 12 (5–24) |
| Physician global assessment (0–100 mm), median (IQR) | 10 (0–12) | 8 (0–18) | 5 (0–10) |
| mHAQ, mean (SD) | 0.26 (0.31) | 0.29 (0.33) | 0.17 (0.23) |
| hsCRP, median (IQR) | 1.75 (0.75–3.13) | 1.64 (0.71–3.13) | 2.39 (0.98–3.20) |
| SDAI, n (%) | |||
| Remission | 22 (24) | 12 (18) | 10 (40) |
| Low disease activity | 41 (44) | 32 (47) | 9 (36) |
| Moderate disease activity | 24 (25) | 21 (31) | 3 (12) |
| High disease activity | 6 (7) | 3 (4) | 3 (12) |
| Mean (SD) | 10.2 (8.7) | 10.6 (8.0) | 9.3 (10.3) |
| DAS28 (hsCRP), n (%) | |||
| Remission | 39 (42) | 25 (37) | 14 (56) |
| Low disease activity | 23 (25) | 18 (27) | 5 (20) |
| Moderate disease activity | 28 (30) | 23 (34) | 5 (20) |
| High disease activity | 3 (3) | 2 (3) | 1 (4) |
| Mean (SD) | 2.56 (1.04) | 2.67 (1.01) | 2.27 (1.07) |
| ACR/EULAR remission, n (%) | 25 (27) | 13 (19) | 12 (48) |
| Medication, n (%) | |||
| bDMARDs (present) | 54 (58) | 41 (60) | 13 (52) |
| cDMARDs (present) | 74 (80) | 54 (79) | 20 (80) |
| Corticosteroids (any form during last year) | 39 (42) | 29 (43) | 10 (40) |
*Total sum is 101% due to rounding.
ACPA, anti-citrullinated protein antibody;ACR, American College of Rheumatology;ACSM, American College of Sports Medicine;AHA, American Heart Association;bDMARDs, biological disease-modifying anti-rheumatic drugs;cDMARDs, conventional disease-modifying anti-rheumatic drugs;COPD, chronic obstructive pulmonary disease;CRPD, chronic restrictive pulmonary disease;DAS28, disease activity score index;EULAR, European League Against Rheumatism;hsCRP, high-sensitivity C reactive protein;HT, hypertension;mHAQ, modified Health Assessment Questionnaire;MI, myocardial infarction;PA index, physical activity summary index;RF, rheumatoid factor;SDAI, Simple Disease Activity Index.
Figure 2VO2peak in RA patients compared with healthy controls. (A) Mean VO2peak in RA population compared with means and 95% CIs of HUNT3 Fitness study. (B) VO2peak results for RA population, median (IQR). RA, rheumatoid arthritis.
Variables associated with VO2peak in the standardised regression model*
| Variable | P value | Standardised |
| Body mass index | <0.001 | −0.25 |
| Physical activity summary index | <0.001 | 0.21 |
| Patient global assessment | 0.006 | −0.14 |
| Systolic blood pressure | 0.016 | −0.12 |
| Resting heart rate | 0.032 | −0.11 |
| Smoking | 0.046 | −0.10 |
*The model was adjusted for age and gender. The standardised coefficient gives the change of VO2peak (mL/(kg x min)) for one SD increase in each variable.
Figure 3Associations of VO2peak to significant predictors. Influence of age (A), body mass index (BMI) (B), systolic blood pressure (SBP) (C), resting heart rate (RHR) (D), physical activity index (E) and patient global assessment (PGA) (F) on VO2peak, based on the multivariable model including age, gender, BMI, RHR, smoking, SBP, physical activity index and PGA. Circles: women; diamonds: men; grey areas: 95% CIs.